Aptevo Therapeutics Files S-1 Registration

TL;DR

APVO filed an S-1, get ready for potential stock dilution or a capital raise.

AI Summary

Aptevo Therapeutics Inc. filed an S-1 registration statement on June 14, 2024, to register an unspecified number of securities. The company, incorporated in Delaware with its principal executive offices in Seattle, WA, operates in the Pharmaceutical Preparations sector. This filing indicates potential future stock offerings or sales by the company.

Why It Matters

This S-1 filing signals Aptevo Therapeutics' intention to potentially offer new securities, which could impact its stock price and capital structure.

Risk Assessment

Risk Level: medium — S-1 filings often precede stock offerings, which can lead to dilution or signal a need for capital, introducing uncertainty.

Key Numbers

• 333-280226 — SEC File Number (Identifies the specific SEC registration)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• 20240614 (date) — Filing Date
• 2834 (number) — Standard Industrial Classification Code
• 811567056 (number) — IRS Number
• DE (jurisdiction) — State of Incorporation
• 2401 4th Avenue, Suite 1050 Seattle, Washington, 98121 (address) — Principal Executive Offices
• 206-838-0500 (phone_number) — Business Phone Number
• Marvin L. White (person) — President and Chief Executive Officer
• Sean M. Donahue (person) — Copies to Counsel
• Paul Hastings LLP (company) — Counsel

FAQ

Key Financial Figures

• $0.001 — #x201d;) of our common stock, par value $0.001 per share (common stock) together with
• $0.83 — sumed combined public offering price of $0.83 per share and common warrant (the last
• $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
• $250,000 — cement agent fee, will be approximately $250,000. The delivery of the shares of common

Filing Documents

• apvo-2024-s1_-_june_offe.htm (S-1) — 876KB
• apvo-ex4_19.htm (EX-4.19) — 152KB
• apvo-ex4_20.htm (EX-4.20) — 154KB
• apvo-ex4_21.htm (EX-4.21) — 301KB
• apvo-ex4_22.htm (EX-4.22) — 154KB
• apvo-ex5_1.htm (EX-5.1) — 32KB
• apvo-ex23_1.htm (EX-23.1) — 4KB
• apvo-exfiling_fees.htm (EX-FILING FEES) — 101KB
• img57496738_0.jpg (GRAPHIC) — 5KB
• img160838558_0.jpg (GRAPHIC) — 2KB
• img230728392_0.jpg (GRAPHIC) — 7KB
• img230728392_1.jpg (GRAPHIC) — 59KB
• img230728392_2.jpg (GRAPHIC) — 516KB
• img230728392_3.jpg (GRAPHIC) — 4KB
• 0000950170-24-073737.txt ( ) — 2594KB

USE OF PROCEEDS

USE OF PROCEEDS 10 CAPITALIZATION 11

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 14

description of securities we are offering

description of securities we are offering 19 PLAN OF DISTRIBUTION 23 I ncorporation of certain information by reference 26 WHERE YOU CAN FIND MORE INFORMATION 26 LEGAL MATTERS 27 EXPERTS 27 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “ Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “ Incorporation of Certain Information by Reference ,” before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have bee

View Full Filing

View this S-1 filing on SEC EDGAR